75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - CONDENSED UNAUDITED INTERIM STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - CONDENSED UNAUDITED INTERIM STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - CONDENSED UNAUDITED INTERIM STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - CONDENSED UNAUDITED INTERIM STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Prepaids and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Convertible Promissory Notes link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Commitments and Contingencies, Including License and Sponsored Research Agreements link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - DRL Development Agreement link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Prepaids and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Organization and Description of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Significant Expense Categories Regularly Reviewed CODM (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Changes in Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares of Common Stock Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Fair Value Measurements - Summary of Company's Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Prepaids and Other Current Assets - Schedule of Prepaids and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Commitments and Contingencies, Including License and Sponsored Research Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Commitments and Contingencies, Including License and Sponsored Research Agreements - Additional Information (Details) [Default] link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding to Acquire Shares of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Stock-based compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation in Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation in Statement of Operations (Details) [Default] link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Stock-based compensation - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Stock-based compensation - Summary of Estimated Black-Scholes Option-Pricing Model Using the Weighted-Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Stock-based compensation - Summary of RSU Stock-Based Payment Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - DRL Development Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - DRL Development Agreement - Additional Information (Details1) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - DRL Development Agreement - Additional Information (Details1) [Default] link:presentationLink link:calculationLink link:definitionLink One-time payment DRL Development Agreement One Time Payment Drl development agreement one time payment. Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation and Significant Accounting Policies Dosing Milestone Dosing Milestone [Member] Dosing milestone. Common Stock, Capital Shares Reserved for Future Issuance Shares were available for future issuance Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Preferred Stock, Shares Issued Series A convertible preferred stock, shares issued Convertible Promissory Notes Debt Disclosure [Text Block] Over-Allotment Over-Allotment Option [Member] Underwritten Public Offering Share-Based Payment Arrangement, Plan Modification, Incremental Cost Total incremental stock-based compensation expense Commitments and Contingencies Commitments and contingencies (Note 6) Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares of common stock outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Minimum [Member] Minimum Maximum Funding Maximum funding. Maximum funding Private Placement Private Placement [Member] Placement Agent Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Series A convertible preferred stock, shares outstanding Fair Value, Recurring Fair Value, Recurring [Member] Pre-approval regulatory milestone payments Pre-Approval Regulatory Milestone Payments Pre-Approval Regulatory Milestone Payments DRL Development Agreement. DRL Development Agreement [Member] DRL Collaboration Agreement DRL Development Agreement Common Stock, Shares, Issued Common stock, shares issued Income tax expense Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total RSU Restricted Stock Unit Awards Restricted Stock Units (RSUs) [Member] Beginning balance Contract with Customer, Liability Contract with Customer, Liability, Total Ending balance Sponsored research agreement. Sponsored Research Agreement [Member] Sponsored Research Agreement Two thousand twenty three private placement. Two Thousand Twenty Three Private Placement [Member] 2023 Private Placement Common stock remained available for sale Common Stock, Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Percentage of increase in number of shares reserved for issuance General and Administrative Expense General and administrative Total general and administrative expenses Income Statement [Abstract] Sponsored research Sponsored Research Sponsored research. Earnings Per Share, Basic Net loss per share of common stock, basic Earnings Per Share, Basic, Total Document Period End Date Document Period End Date Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted, Weighted average exercise price Common Stock, Shares Authorized Common stock, shares authorized Statement of Stockholders' Equity [Abstract] Other Prepaid Expense, Current Prepaid other Prepaid Expense and Other Assets, Current Prepaids and other current assets Prepaids and other current assets Warrants granted Class Of Warrant Or Right Granted During Period Class of warrant or right granted during period. Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at January 1, 2026, Aggregate intrinsic value Outstanding at June 30, 2026, Aggregate intrinsic value Outstanding at January 1, 2026, Aggregate intrinsic value Outstanding at June 30, 2026, Aggregate intrinsic value The entire disclosure for development agreement. Development Agreement Disclosure [Text Block] DRL Development Agreement Assets Total assets Title of 12(b) Security Security12b Title Common stock warrants. Common Stock Warrants [Member] Common Stock Warrants Preferred Stock, Value, Issued Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued or outstanding as of June 30, 2026 or December 31, 2025 Beginning balance at January 1, 2024, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Ending balance at September 30, 2024, Number of Shares Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted, Options Awarded, Number of Shares Summary of RSU Stock-Based Payment Awards Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name ALS IND Milestone [Member] Als ind milestone. ALS IND Milestone DRL Agreement License and Supply Agreement [Member] License and supply agreement. Location, Statement of Financial Position, Balance [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Outstanding Weighted average remaining contractual (years) at January 1, 2021 Outstanding, Weighted average remaining contractual term (years) Service-based stock options that generally have a contractual life Segment Reporting [Table Text Block] Summary of Significant Expense Categories Regularly Reviewed CODM Significant accounting policies. Significant Accounting Policies [Table] Significant Accounting Policies [Table] Balance Equity, Attributable to Parent Balance Total stockholders' equity Other Assets, Noncurrent Other assets Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Basis of Presentation Basis of Accounting, Policy [Policy Text Block] First Amendment First Amendment [Member] First amendment member. Stock, Class of Stock [Table] Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Statistical Measurement [Axis] Statistical Measurement Entity Interactive Data Current Entity Interactive Data Current Percentage of royalties owed on sublicense income. Percentage of Royalties Owed on Sublicense Income Percentage of royalties owed on sublicense income Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Summary of Stock Based Compensation in Statement of Operations In Process Research and Development, Policy [Policy Text Block] In-Process Research and Development Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest at June 30, 2026, Weighted average remaining contractual term (years) Patent know how and license agreement. Patent Know How And License Agreement [Member] Methodist License Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Common Stock, Value, Issued Common stock issued Common stock, $0.0001 par value; 200,000,000 shares authorized; 23,457,849 and 20,934,456 shares issued and outstanding as of June 30, 2026 or December 31, 2025, respectively Property, Plant, and Equipment [Policy Text Block] Fixed Assets Liabilities Total liabilities Total liabilities In-process research and development. Acquired in-process research and development assets In-process Research And Development In-process research and development Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Company's Assets Measured at Fair Value on a Recurring Basis Product and Service [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Other Nonoperating Income (Expense) [Abstract] Other income: Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents (money market funds), Fair Value Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Operating Expenses Total operating expenses Initial Public Offering and Over-Allotment Option Initial Public Offering and Over-Allotment Option [Member] Initial public offering and overallotment option. Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Description of Business Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Schedule of Warrants Outstanding to Acquire Shares of Common Stock Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Sale of common stock in offering and overallotment option, net of issuance costs (in shares) Stock issued during period, shares Sale of common stock, net of issuance costs (in shares) Class of warrant purchase Class of Warrant or Right, Outstanding Outstanding Initial Public Offering IPO [Member] IPO Methodist research fund Methodist research fund. Methodist Research Fund Intangible Asset, Finite-Lived, Cost Incurred to Renew or Extend [Policy Text Block] Patent Costs Income Tax, Policy [Policy Text Block] Income Taxes Subsequent Events Subsequent Events [Text Block] Other General and Administrative Expense Other general and administrative expenses Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Assets, Fair Value Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Labor and Related Expense Employee related costs Payments of Stock Issuance Costs Payment for Series A offerings costs Net of issuance costs Research and Development Expense (Excluding Acquired in Process Cost) Research and development Total research and development expenses Beginning balance at January 1, 2024, Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Ending balance at September 30, 2024, Weighted average grant date fair value Liabilities and Equity Total liabilities and stockholders' equity Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Research and Development Expense Research and development expenses Research and Development Expense, Total Document Fiscal Period Focus Document Fiscal Period Focus Revenue, Remaining Performance Obligation, Amount Transaction price allocated to performance obligation Prepaid Expense and Other Assets, Current [Abstract] Underwriters Underwriters [Member] Underwriters. Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Estimated Black-Scholes Option-Pricing Model Using the Weighted-Average Assumptions Accrued research and development. Accrued Research And Development Accrued research and development Class Of Warrant Or Right Forfeited During Period Class of warrant or right forfeited during period. Warrants Forfeited Sale of Stock [Axis] Entity Current Reporting Status Entity Current Reporting Status Use of Estimates, Policy [Policy Text Block] Use of Estimates Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable at June 30, 2026, Options January Two Thousand Twenty Six Offering [Member] January two thousand twenty six offering. January 2026 Offering Fair Value, Inputs, Level 1 [Member] Level 1 Class of Stock [Domain] Class of Stock Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Preclinical product candidates Preclinical Product Candidates Preclinical product candidates. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares of Common Stock Outstanding Increase (Decrease) in Other Noncurrent Assets Other assets Document Transition Report Document Transition Report Commitments and Contingencies Disclosure [Abstract] Class of Warrant or Right [Axis] Royalties percentage related to customary reductions Royalties percentage related to customary reductions. Liabilities, Current [Abstract] Current liabilities: Warrants and Rights Note Disclosure [Abstract] Share-Based Payment Arrangement [Abstract] Common Stock [Member] Common Stock Statistical Measurement Statistical Measurement [Domain] Equity, Attributable to Parent [Abstract] Stockholders' equity: Weighted Average Number of Shares Outstanding, Basic Weighted-average shares of common stock outstanding, basic Weighted Average Number of Shares Outstanding, Basic, Total Assets [Abstract] Assets Entity Central Index Key Entity Central Index Key Antidilutive Securities [Axis] Antidilutive Securities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Exercisable at June 30, 2026, Aggregate intrinsic value Class of Stock [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Class of Warrant or Right [Domain] Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Accrued Liabilities, Total Document Quarterly Report Upfront nonrefundable payment receivable. Upfront Nonrefundable Payment Receivable Upfront nonrefundable payment receivable January Two Thousand Twenty Six Private Placement [Member] January two thousand twenty six private placement. January 2026 Private Placement Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding Weighted average exercise price at December 31, 2021 Outstanding at January 1, 2026, Weighted average exercise price Outstanding at June 30, 2026, Weighted average exercise price Granted and Vested, Number of Shares Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Granted and Vested in Period Share based compensation arrangement by share based payment award equity instruments other than options granted and vested in period. Schedule of Prepaids and Other Current Assets Tabular disclosure of prepaids and other current assets. Summary Of Prepaids And Other Current Assets [Table Text Block] Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Entity Incorporation, State or Country Code Entity Incorporation State Country Code Earnings Per Share, Diluted Net loss per share of common stock, diluted Earnings Per Share, Diluted, Total Sale of Stock, Number of Shares Issued in Transaction Shares issued Series A convertible preferred stock, par value Preferred Stock, Par or Stated Value Per Share Stock issued during the period, value of converted notes Net loss Net loss Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies, Including License and Sponsored Research Agreements Preferred Stock, Liquidation Preference, Value Series A convertible preferred stock, liquidation value Measurement Frequency [Domain] Measurement Frequency Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Summary of Changes in Deferred Revenue Equity Components [Axis] Equity Components Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash flows from investing activities: Purchase of in-process research and development assets Payments to Acquire in Process Research and Development Research And Development Services And License [Member] Research And Development Services And License. R&D Services and License Statement of Cash Flows [Abstract] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised, Weighted average exercise price At-The-Market Offering Program [Member] At-The-Market Offering Program. ATM Offering Program Revenue [Policy Text Block] Collaboration Revenues Prepaids and other current assets Increase (Decrease) in Prepaid Expense and Other Assets License termination condition description. License Termination Condition Description License termination condition description. Royalty payments DRL Development Agreement Royalty Payments Drl development agreement royalty payments. Internal research and development expenses, including stock-based compensation Internal Research and Development Expenses, Including Stock-based Compensation Internal research and development expenses, including stock-based compensation. Fair Value Disclosures [Text Block] Fair Value Measurements Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Maximum aggregate amount payable upon milestone achievement of specific development and regulatory events. Maximum Aggregate Amount Payable Upon Milestone Achievement Of Specific Development And Regulatory Events Maximum aggregate amount payable upon milestone achievement of specific development and regulatory events. Preferred Stock, Shares Authorized Series A convertible preferred stock, shares authorized Preferred stock, shares authorized Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Class of Stock Class of Stock [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share, amount Class of Warrant or Right [Line Items] Number of Operating Segments Number of operating segments Increase (Decrease) in Deferred Revenue Deferred collaboration revenue Compensation Related Costs, Policy [Policy Text Block] Stock-based Compensation Prepaid And Other Current Assets [Text Block] Prepaid and other current assets. Prepaids and Other Current Assets Deferred Charges, Policy [Policy Text Block] Deferred financing costs Segment Reporting, Policy [Policy Text Block] Segment Information Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited, Weighted average exercise price Accrued Liabilities, Current Accrued expenses Accrued expenses Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding Options at December 31, 2021 Outstanding at January 1, 2026, Options Outstanding at June 30, 2026, Options Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Document Type Document Type Convertible Promissory Notes Convertible Debt [Member] Convertible Notes Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Cumulative Effect, Period of Adoption [Domain] Stock Options Operating Income (Loss) Loss from operations Financing costs related to the ATM Offering Program in accounts payable Financing Costs Related To The At-The-Market Offering Program In Accounts Payable Financing costs related to the at-the-market offering program in accounts payable. Sale of stock per share Sale of Stock, Price Per Share Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Securities Act File Number Entity File Number Allocated Share Based Compensation Expense Related to General and Administrative Expenses Allocated share based compensation expense related to general and administrative expenses. Stock-based compensation Location, Statement of Income, Balance [Axis] Long-Lived Asset, Excluding Intangible Asset and Goodwill, Impairment and Disposal [Policy Text Block] Long-Lived Assets Retained Earnings [Member] Accumulated Deficit Entity Registrant Name Entity Registrant Name Accounting Policies [Abstract] Depreciation Depreciation Depreciation, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total First combination product. First Combination Product Member First Combination Product Entity Address, Address Line One Entity Address Address Line1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of stock options (in shares) Exercised, Options Issuance of common stock upon exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at June 30, 2026, Weighted average exercise price Total current assets Assets, Current Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Derivatives, Policy [Policy Text Block] Convertible Notes and Derivative Liability Payments of Financing Costs Payments of Financing Costs, Total Payment of financing costs related to the ATM Offering Program Entity Small Business Entity Small Business Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest at June 30, 2026 Aggregate intrinsic value Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation cost Long-Term Debt, Type [Axis] Long-Term Debt, Type General and administrative expenses: Selling, General and Administrative Expense [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Transaction price DRL Development Agreement Transaction Price Drl development agreement transaction price. Per share information: Earnings Per Share [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Options Activity Conversion of convertible preferred stock upon initial public offering Conversion of Convertible Preferred Stock upon Initial Public Offering Conversion of convertible preferred stock upon initial public offering. October Two Thousand And Twenty Five Offering [Member] October two thousand and twenty five offering. October 2025 Offering Plan Name [Axis] Plan Name Equity [Abstract] Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Uncertain tax positions, interest, or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total Product and Service [Domain] Class of Warrant or Right [Table] Equity [Text Block] Stockholders' Equity Measurement Frequency [Axis] Measurement Frequency Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Series A convertible preferred stock. Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock Entity Tax Identification Number Entity Tax Identification Number Equity Component [Domain] Equity Component Entity Address, City or Town Entity Address City Or Town Stock Issued During Period, Value, New Issues Sale of common stock, net of issuance costs Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Financing Costs Related To Sale Of Common Stock In Accounts Payable Financing costs related to sale of common stock in accounts payable. Financing costs related to the sale of common stock in accounts payable Segment Reporting, Expense Information Used by CODM, Description Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Combination product. Combination Product Member Combination Product Statement [Table] Statement [Table] Deferred Revenue, Current, Total Deferred Revenue, Current Deferred collaboration revenue Deferred revenue Stock-based compensation expense Share-Based Payment Arrangement, Expense Stock-based compensation Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Pre-tax loss Pre-tax loss Entity Shell Company Entity Shell Company Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash used in investing activities Statement [Line Items] Statement [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Deferred collaboration revenue. Deferred Collaboration Revenue Deferred collaboration revenue Maximum [Member] Maximum Mono product. Mono Product [Member] Mono Product Debt Disclosure [Abstract] Sale of Stock [Domain] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Net decrease in cash and cash equivalents Subsequent Events [Abstract] Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Subscription receivable related to warrant exercise. Subscription Receivable Related To Warrant Exercise Subscription receivable related to warrant exercise Assets, Current [Abstract] Current assets: Aggregate regulatory milestone payable Aggregate Regulatory Milestone Payable Aggregate regulatory milestone payable. Accrued Professional Fees, Current Accrued professional fees Document Fiscal Year Focus Document Fiscal Year Focus Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Collaborative Arrangement and Arrangement Other than Collaborative [Table] Entity Ex Transition Period Entity Ex Transition Period Contract with Customer, Liability, Revenue Recognized Transaction price allocated to performance obligation, revenue recognized Recognition of unearned revenue Other Accrued Liabilities, Current Accrued other Security Exchange Name Security Exchange Name Financing costs related to the sale of common stock in accounts payable Financing Costs Related To The Sale Of Common Stock In Accounts Payable Financing costs related to the sale of common stock in accounts payable. Revenues, Total Revenues Collaboration revenue New Accounting Pronouncements, Policy [Policy Text Block] Recently issued but not yet adopted accounting pronouncements Warrant [Member] Common Stock Warrants Warrant Class of warrant exercise price Exercise price per share Exercise price per share Entity Address, State or Province Entity Address State Or Province Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average amortization period Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Common stock were authorized to be issued Amendment Flag Amendment Flag First Mono Product Member First Mono Product Member First Mono Product Share-Based Payment Arrangement [Text Block] Stock-based compensation Achievement of sales milestones. Achievement Of Sales Milestones Sales milestones Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Other income, net Other income Other income 2021 Equity Incentive Plan. Two Thousand Twenty One Equity Incentive Plan [Member] 2021 Equity Incentive Plan City Area Code City Area Code Unrecognized Tax Benefits Unrecognized Tax Benefits, Ending Balance Unrecognized Tax Benefits, Beginning Balance Unrecognized income tax benefits Conversion of convertible preferred stock upon initial public offering Conversion of convertible promissory notes upon initial public offering Conversion of convertible promissory notes upon initial public offering Conversion Of Convertible Promissory Notes Upon Initial Public Offering. Gross proceeds from sale of common stock, maximum commission rate percent to pay Gross Proceeds From Sale Of Common Stock, Maximum Commission Rate Percent Gross proceeds from sale of common stock, maximum commission rate percent. Organization, Consolidation and Presentation of Financial Statements [Abstract] Proceeds from Issuance of Common Stock Gross proceeds from the Offering Proceeds from sale of common stock, net of offering costs Research and Development Expense [Abstract] Research and development expenses: Prepaid research and development Prepaid Research And Development Prepaid research and development. Operating expenses: Accrued Employee Benefits, Current Accrued payroll Common Stock, Par or Stated Value Per Share Common stock, par value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term Exercisable at June 30, 2026, Weighted average remaining contractual term (years) Significant accounting policies. Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Lessee, Leases [Policy Text Block] Leases Minimum annual amount owned upon commercialization. Minimum Annual Amount Owned Upon Commercialization Minimum annual amount owned upon commercialization Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest Options at December 31, 2021 Options, Vested and expected to vest Vested and expected to vest at June 30, 2026, Options Liabilities, Current Total current liabilities Noncash Investing and Financing Items [Abstract] Supplemental disclosures of non-cash investing and financing activities: In Process Research and Development Costs in Accrued Expenses In process research and development costs in accrued expenses. In-process research and development costs in accrued expenses Granted and Vested, Weighted average grant date fair value Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Grants in Period Weighted Average Granted and Vested Date Fair Value Share based compensation arrangement by share based payment award equity instruments other than options grants in period weighted average granted and vested date fair value. Cash and cash equivalents as of end of the period Cash and cash equivalents as of beginning of the period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Clinical product candidates Clinical Product Candidates Clinical product candidates. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Research And Development Services. Research And Development Services [Member] R&D Services Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Additional Paid-in Capital [Member] Additional Paid-in Capital License agreement upfront fee. License Agreement Upfront Fee License agreement upfront fee Plan Name [Domain] Plan Name October 2024 Private Placement October Two Thousand Twenty Four Private Placement [Member] October two thousand twenty four private placement. Prepaid Insurance Prepaid insurance ARScience License Agreement ARScience Biotherapeutics, Inc. ARScience Biotherapeutics, Inc. [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Exercised, Aggregate intrinsic value Cover [Abstract] Achievement of developmental milestones Achievement of Developmental Milestones Developmental milestones Long-Term Debt, Type [Domain] Long-Term Debt, Type Expiration date Wrrants Or Right, Expiration Date Wrrants Or Right, Expiration Date Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Stock-based compensation, including the issuance of restricted stock Share-Based Payment Arrangement, Noncash Expense Share-Based Payment Arrangement, Noncash Expense, Total Additional Paid in Capital Additional paid-in capital Additional Paid in Capital, Total Contract with Customer, Liability, Deferral of Revenue Contract with customer, liability, deferral of revenue. Deferral of revenue Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustment to reconcile net loss to net cash used in operating activities: Fair Value Disclosures [Abstract] Cash and Cash Equivalent Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents (money market funds), Carrying Value Additional payments of other development and sales milestones Additional Payments of Other Development and Sales Milestones Additional payments of other development and sales milestones. Class Of Warrant Or Right Exercised During Period Class of warrant or right exercised during period. Warrants Exercised Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Payables and Accruals [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Forfeited, Options Forfeited, Options Entity Filer Category Entity Filer Category Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest, Weighted average exercise price at December 31, 2021 Weighted average exercise price, Vested and expected to vest Vested and expected to vest at June 30, 2026, Weighted average exercise price Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Fixed assets, net Property, plant and equipment, net Cumulative Effect, Period of Adoption [Axis] Shares, Outstanding Ending balance, shares Beginning balance, shares Entity Address, Postal Zip Code Entity Address Postal Zip Code Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Estimated fair value of the Company's common stock per share Statement of Financial Position [Abstract] Local Phone Number Local Phone Number